GlaxoSmithKline raised eyebrows last year when it paid $5.1 billion for Tesaro and its PARP inhibitor Zejula, amid suggestions it had paid too much. Now, a positive phase 3 trial for the drug will ...

Tesaro already has ongoing collaborations with Merck in treating forms of breast cancer and ovarian cancer. Additionally, the firm is working with Johnson & Johnson to develop Zejula to treat ...

Gilead Sciences is ready to shop. Here's why Kite, Tesaro, and Intercept might be good selections to add to the biotech's cart. Gilead CEO John Milligan mentioned in the last earnings call that ...

Dr Mary Lynne Hedley, a trailblazer in biotechnology and scientific entrepreneurship, recently visited Cyprus to inspire the next generation of life science innovators. A Senior Scientific Fellow at ...